ECM
BMY icon

EagleClaw Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

EagleClaw Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23M Sell
36,693
-7,725
-17% -$450K 0.31% 74
2025
Q4 		$2.4M Sell
44,418
-1,750
-4% -$84.2K 0.35% 74
2025
Q3 		$2.08M Sell
46,168
-1,550
-3% -$72.4K 0.29% 78
2025
Q2 		$2.21M Sell
47,718
-1,600
-3% -$78.5K 0.33% 77
2025
Q1 		$3.01M Sell
49,318
-2,700
-5% -$157K 0.47% 59
2024
Q4 		$2.94M Sell
52,018
-4,600
-8% -$257K 0.47% 62
2024
Q3 		$2.93M Sell
56,618
-2,050
-3% -$96.2K 0.49% 61
2024
Q2 		$2.44M Sell
58,668
-700
-1% -$31.3K 0.44% 68
2024
Q1 		$3.22M Buy
59,368
+1,136
+2% +$57.9K 0.58% 53
2023
Q4 		$2.99M Sell
58,232
-8,275
-12% -$434K 0.62% 53
2023
Q3 		$3.86M Buy
66,507
+1,250
+2% +$76.6K 0.88% 40
2023
Q2 		$4.17M Buy
65,257
+75
+0.1% +$5.03K 0.96% 38
2023
Q1 		$4.52M Sell
65,182
-190
-0.3% -$13.4K 1.07% 36
2022
Q4 		$4.7M Buy
65,372
+100
+0.2% +$7.54K 1.14% 28
2022
Q3 		$4.64M Buy
65,272
+2,100
+3% +$152K 1.3% 26
2022
Q2 		$4.86M Sell
63,172
-2,500
-4% -$190K 1.32% 25
2022
Q1 		$4.8M Sell
65,672
-600
-0.9% -$40.3K 1.1% 29
2021
Q4 		$4.13M Buy
66,272
+1,825
+3% +$107K 0.91% 34
2021
Q3 		$3.82M Buy
64,447
+1,800
+3% +$119K 0.99% 34
2021
Q2 		$4.19M Buy
62,647
+3,800
+6% +$248K 1.08% 28
2021
Q1 		$3.72M Buy
58,847
+7,210
+14% +$449K 1.07% 28
2020
Q4 		$3.21M Buy
51,637
+200
+0.4% +$12.3K 1.02% 29
2020
Q3 		$3.1M Buy
51,437
+3,705
+8% +$223K 1.09% 28
2020
Q2 		$2.82M Sell
47,732
-1,500
-3% -$89.7K 1.09% 27
2020
Q1 		$2.75M Buy
49,232
+1,425
+3% +$87.1K 1.3% 25
2019
Q4 		$3.07M Buy
47,807
+14,125
+42% +$809K 1.12% 27
2019
Q3 		$1.7M Buy
33,682
+21,395
+174% +$1.01M 0.69% 49
2019
Q2 		$557K Buy
12,287
+1,665
+16% +$77.6K 0.24% 85
2019
Q1 		$508K Hold
10,622
– – 0.23% 87
2018
Q4 		$550K Hold
10,622
– – 0.29% 78
2018
Q3 		$658K Buy
10,622
+200
+2% +$11.9K 0.29% 77
2018
Q2 		$577K Hold
10,422
– – 0.28% 76
2018
Q1 		$659K Buy
10,422
+200
+2% +$12.9K 0.33% 73
2017
Q4 		$625K Hold
10,222
– – 0.32% 73
2017
Q3 		$653K Hold
10,222
– – 0.37% 69
2017
Q2 		$570K Hold
10,222
– – 0.33% 72
2017
Q1 		$556K Hold
10,222
– – 0.33% 74
2016
Q4 		$598K Hold
10,222
– – 0.38% 71
2016
Q3 		$551K Sell
10,222
-50
-0.5% -$3.21K 0.35% 73
2016
Q2 		$757K Sell
10,272
-300
-3% -$21.2K 0.5% 62
2016
Q1 		$676K Sell
10,572
-100
-0.9% -$6.31K 0.46% 62
2015
Q4 		$734K Sell
10,672
-200
-2% -$13.2K 0.49% 62
2015
Q3 		$643K Hold
10,872
– – 0.45% 63
2015
Q2 		$725K Buy
10,872
+200
+2% +$13.2K 0.46% 63
2015
Q1 		$690K Sell
10,672
-50
-0.5% -$3.13K 0.45% 64
2014
Q4 		$633K Buy
10,722
+600
+6% +$33.8K 0.42% 69
2014
Q3 		$518K Hold
10,122
– – 0.35% 72
2014
Q2 		$492K Sell
10,122
-500
-5% -$24.6K 0.33% 77
2014
Q1 		$552K Buy
+10,622
New +$565K 0.4% 71

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EagleClaw Capital Management's BMY Position: Q1 2026 in Review

EagleClaw Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 17% in Q1 2026, selling an estimated $450K and leaving 36,693 shares worth $2.23M. The position accounts for 0.31% of the portfolio, ranked #74.

EagleClaw Capital Management first reported a position in BMY in Q1 2014 and has held it in 49 quarters since. The position peaked at $4.86M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • EagleClaw Capital Management held 36,693 shares of Bristol-Myers Squibb worth $2.23M as of Q1 2026.
  • EagleClaw Capital Management sold 7,725 Bristol-Myers Squibb shares in Q1 2026, an estimated $450K.
  • Bristol-Myers Squibb made up 0.31% of EagleClaw Capital Management's portfolio in Q1 2026, its #74 holding.
  • EagleClaw Capital Management first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 49 quarters since.
  • EagleClaw Capital Management's Bristol-Myers Squibb position peaked at $4.86M in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on EagleClaw Capital Management's 13F filing for Q1 2026, filed 8 May 2026.